Peptide nucleic acid precursors and methods of preparing same
First Claim
1. A protected precursor which readily provides a peptide nucleic acid (PNA), said precursor consisting essentially of a cyclic substituted piperazinone having a nucleotide base covalently linked directly to one nitrogen in said cyclic piperazinone ring and having a first protecting group covalently linked to the other nitrogen in said piperazinone ring, said substituted piperazinone constituting an intermediate, which precursor may be readily hydrolyzed to a peptide nucleic acid monomer or reacted with a nucleophile to form a PNA derivative or an oligomer.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel and efficient syntheses create novel piperazinone intermediates which facilitate the production and use of PNAs. Such syntheses and the products enhance the feasibility of a system which permits the rapid identification of PNA oligomers useful as therapeutics, diagnostics and/or gene characterization tools. A first component of the system is a universal PNA library that most preferably incorporates one or more universal nucleotide bases into carefully selected positions within each oligomer species thereby providing the library with the screening ability of a much larger library. The second component of the system is a high throughput screening system that includes a number of assays designed to provide information on the binding activities of the different PNAs to a target nucleotide sequence (generally, a DNA or RNA sequence). The third component is a software system especially designed to provide rapid analysis of the data collected from the high throughput screening system and to determine therefrom the sequence base identities and sequence lengths of PNA oligomers most likely to bind to and appropriately affect the target molecule.
101 Citations
18 Claims
- 1. A protected precursor which readily provides a peptide nucleic acid (PNA), said precursor consisting essentially of a cyclic substituted piperazinone having a nucleotide base covalently linked directly to one nitrogen in said cyclic piperazinone ring and having a first protecting group covalently linked to the other nitrogen in said piperazinone ring, said substituted piperazinone constituting an intermediate, which precursor may be readily hydrolyzed to a peptide nucleic acid monomer or reacted with a nucleophile to form a PNA derivative or an oligomer.
-
7. A method for preparing a protected precursor, which method comprises the steps of:
-
a) mixing ethylene diamine and a haloacetic acid equivalent having the formula Y—
CH2CO—
X where X is hydrogen, halogen or OR, with R being hydrogen or lower alkyl, and Y is a leaving group, in solution;
b) heating said mixture of step (a) to form a cyclic piperazinone;
c) covalently coupling a nucleotide base to said cyclic piperazinone to create a base-substituted piperazinone; and
d) providing protection for an amido moiety of the product of step (c) to form an activated intermediate which serves as a precursor that may be readily hydrolyzed to a peptide nucleic (PNA) acid monomer or reacted with a nucleophile to form a PNA derivative or an oligomer. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. A method for preparing a protected precursor, which method comprises the steps of:
-
a) carrying out a reductive amination reaction between the α
-amino group of an α
-amino acid or an ester thereof and the carboxyl group of either an N-protected amino aldehyde or an N-protected amino ketone;
b) then deprotecting the primary amino group of the reaction product of a step (a);
c) heating said deprotected reaction product of step (b) to form a cyclic piperazinone;
d) covalently coupling a nucleotide base to said cyclic piperazinone to create a base-substituted piperazinone; and
e) providing protection for an amido moiety of the product of step (d) to form an intermediate which serves as a precursor that may be readily hydrolyzed to a peptide nucleic acid (PNA) monomer or reacted with a nucleophile to form a PNA derivative or an oligomner. - View Dependent Claims (17, 18)
-
Specification